Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial
To study the combination of 5FUDR, recombinant leukocyte interferon (IFN), and doxorubicin in patients with unresectable hepatocellular carcinoma. IFN was administered at a dose of 6 miu/m(2) subcutaneously followed in 2 h by doxorubicin 20 mg/m(2) intravenously. After doxorubicin, 5FUDR was given a...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2003, Vol.129 (1), p.17-20 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 20 |
|---|---|
| container_issue | 1 |
| container_start_page | 17 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 129 |
| creator | FEUN, Lynn G OBRIEN, Christopher MOLINA, Enrique RODRIGUEZ, Miguel JEFFERS, Lenox SCHIFF, Eugene R MARINI, Angela SAVARAJ, Niramol ARDALAN, Bach |
| description | To study the combination of 5FUDR, recombinant leukocyte interferon (IFN), and doxorubicin in patients with unresectable hepatocellular carcinoma.
IFN was administered at a dose of 6 miu/m(2) subcutaneously followed in 2 h by doxorubicin 20 mg/m(2) intravenously. After doxorubicin, 5FUDR was given as a 24-h infusion at a starting dose of 80 mg/kg. The dose of IFN was escalated to three times a week if tolerated. Both doxorubicin and 5FUDR were administered once weekly.
There were 30 patients entered into the study. Among the 30 patients, there were two partial responses (7%) and one patient had stable disease. Toxicity was generally tolerable with fever, and chills, fatigue, and myelosuppression as the most common side effects.
This chemotherapy combination was generally well tolerated, but has limited activity in unresectable, advanced hepatocellular carcinoma. |
| doi_str_mv | 10.1007/s00432-002-0398-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_220525363</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>701911801</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-41745950ecea57a00876491f3259b4ccaaa0199e053d0728e2ab187857990f2f3</originalsourceid><addsrcrecordid>eNpFkMFq3DAQhkVoSLZpH6CXIgq91e1IsizrGNKmXQgUQnMWY-2YVeq1tpJMkrevll3IYRh-8f0j-Bj7IOCrADDfMkCrZANQR9m-kWdsJQ4vQin9hq1AGNFoKbpL9jbnR6hZG3nBLoXsRN_bbsXyPfm4G8KMc-ETLX-jfynEw1wojZTi_IVv4nNMyxB8qAHnDde3D9_vK8L3WALNJfOnULZ8SzVHT9O0TJi4x1QbcYfNNd9vMRNfr3lJAad37HzEKdP7075iD7c__tz8au5-_1zfXN81Xum2NK0wrbYayBNqgwC96VorRiW1HVrvERGEtQRabcDIniQOoje9NtbCKEd1xT4d7-5T_LdQLu4xLmmuXzopQUutOlUhcYR8ijknGt0-hR2mFyfAHSy7o2VXLbuDZSdr5-Pp8DLsaPPaOGmtwOcTgNnjNCacfcivXNu1EpRS_wFwlIQi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220525363</pqid></control><display><type>article</type><title>Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>FEUN, Lynn G ; OBRIEN, Christopher ; MOLINA, Enrique ; RODRIGUEZ, Miguel ; JEFFERS, Lenox ; SCHIFF, Eugene R ; MARINI, Angela ; SAVARAJ, Niramol ; ARDALAN, Bach</creator><creatorcontrib>FEUN, Lynn G ; OBRIEN, Christopher ; MOLINA, Enrique ; RODRIGUEZ, Miguel ; JEFFERS, Lenox ; SCHIFF, Eugene R ; MARINI, Angela ; SAVARAJ, Niramol ; ARDALAN, Bach</creatorcontrib><description>To study the combination of 5FUDR, recombinant leukocyte interferon (IFN), and doxorubicin in patients with unresectable hepatocellular carcinoma.
IFN was administered at a dose of 6 miu/m(2) subcutaneously followed in 2 h by doxorubicin 20 mg/m(2) intravenously. After doxorubicin, 5FUDR was given as a 24-h infusion at a starting dose of 80 mg/kg. The dose of IFN was escalated to three times a week if tolerated. Both doxorubicin and 5FUDR were administered once weekly.
There were 30 patients entered into the study. Among the 30 patients, there were two partial responses (7%) and one patient had stable disease. Toxicity was generally tolerable with fever, and chills, fatigue, and myelosuppression as the most common side effects.
This chemotherapy combination was generally well tolerated, but has limited activity in unresectable, advanced hepatocellular carcinoma.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-002-0398-2</identifier><identifier>PMID: 12618896</identifier><identifier>CODEN: JCROD7</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Cancer ; Carcinoma, Hepatocellular - drug therapy ; Chemotherapy ; Combined treatments (chemotherapy of immunotherapy associated with an other treatment) ; Doxorubicin - administration & dosage ; Drug Administration Schedule ; Female ; Floxuridine - administration & dosage ; Humans ; Infusions, Intravenous ; Interferons - administration & dosage ; Leukocytes ; Liver ; Liver Neoplasms - drug therapy ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Recombinant Proteins - administration & dosage ; Treatment Failure</subject><ispartof>Journal of cancer research and clinical oncology, 2003, Vol.129 (1), p.17-20</ispartof><rights>2003 INIST-CNRS</rights><rights>Copyright Springer-Verlag 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-41745950ecea57a00876491f3259b4ccaaa0199e053d0728e2ab187857990f2f3</citedby><cites>FETCH-LOGICAL-c354t-41745950ecea57a00876491f3259b4ccaaa0199e053d0728e2ab187857990f2f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4009,27902,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14642033$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12618896$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FEUN, Lynn G</creatorcontrib><creatorcontrib>OBRIEN, Christopher</creatorcontrib><creatorcontrib>MOLINA, Enrique</creatorcontrib><creatorcontrib>RODRIGUEZ, Miguel</creatorcontrib><creatorcontrib>JEFFERS, Lenox</creatorcontrib><creatorcontrib>SCHIFF, Eugene R</creatorcontrib><creatorcontrib>MARINI, Angela</creatorcontrib><creatorcontrib>SAVARAJ, Niramol</creatorcontrib><creatorcontrib>ARDALAN, Bach</creatorcontrib><title>Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><description>To study the combination of 5FUDR, recombinant leukocyte interferon (IFN), and doxorubicin in patients with unresectable hepatocellular carcinoma.
IFN was administered at a dose of 6 miu/m(2) subcutaneously followed in 2 h by doxorubicin 20 mg/m(2) intravenously. After doxorubicin, 5FUDR was given as a 24-h infusion at a starting dose of 80 mg/kg. The dose of IFN was escalated to three times a week if tolerated. Both doxorubicin and 5FUDR were administered once weekly.
There were 30 patients entered into the study. Among the 30 patients, there were two partial responses (7%) and one patient had stable disease. Toxicity was generally tolerable with fever, and chills, fatigue, and myelosuppression as the most common side effects.
This chemotherapy combination was generally well tolerated, but has limited activity in unresectable, advanced hepatocellular carcinoma.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cancer</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Chemotherapy</subject><subject>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</subject><subject>Doxorubicin - administration & dosage</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Floxuridine - administration & dosage</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Interferons - administration & dosage</subject><subject>Leukocytes</subject><subject>Liver</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Recombinant Proteins - administration & dosage</subject><subject>Treatment Failure</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpFkMFq3DAQhkVoSLZpH6CXIgq91e1IsizrGNKmXQgUQnMWY-2YVeq1tpJMkrevll3IYRh-8f0j-Bj7IOCrADDfMkCrZANQR9m-kWdsJQ4vQin9hq1AGNFoKbpL9jbnR6hZG3nBLoXsRN_bbsXyPfm4G8KMc-ETLX-jfynEw1wojZTi_IVv4nNMyxB8qAHnDde3D9_vK8L3WALNJfOnULZ8SzVHT9O0TJi4x1QbcYfNNd9vMRNfr3lJAad37HzEKdP7075iD7c__tz8au5-_1zfXN81Xum2NK0wrbYayBNqgwC96VorRiW1HVrvERGEtQRabcDIniQOoje9NtbCKEd1xT4d7-5T_LdQLu4xLmmuXzopQUutOlUhcYR8ijknGt0-hR2mFyfAHSy7o2VXLbuDZSdr5-Pp8DLsaPPaOGmtwOcTgNnjNCacfcivXNu1EpRS_wFwlIQi</recordid><startdate>2003</startdate><enddate>2003</enddate><creator>FEUN, Lynn G</creator><creator>OBRIEN, Christopher</creator><creator>MOLINA, Enrique</creator><creator>RODRIGUEZ, Miguel</creator><creator>JEFFERS, Lenox</creator><creator>SCHIFF, Eugene R</creator><creator>MARINI, Angela</creator><creator>SAVARAJ, Niramol</creator><creator>ARDALAN, Bach</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>2003</creationdate><title>Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial</title><author>FEUN, Lynn G ; OBRIEN, Christopher ; MOLINA, Enrique ; RODRIGUEZ, Miguel ; JEFFERS, Lenox ; SCHIFF, Eugene R ; MARINI, Angela ; SAVARAJ, Niramol ; ARDALAN, Bach</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-41745950ecea57a00876491f3259b4ccaaa0199e053d0728e2ab187857990f2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cancer</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Chemotherapy</topic><topic>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</topic><topic>Doxorubicin - administration & dosage</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Floxuridine - administration & dosage</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Interferons - administration & dosage</topic><topic>Leukocytes</topic><topic>Liver</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Recombinant Proteins - administration & dosage</topic><topic>Treatment Failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FEUN, Lynn G</creatorcontrib><creatorcontrib>OBRIEN, Christopher</creatorcontrib><creatorcontrib>MOLINA, Enrique</creatorcontrib><creatorcontrib>RODRIGUEZ, Miguel</creatorcontrib><creatorcontrib>JEFFERS, Lenox</creatorcontrib><creatorcontrib>SCHIFF, Eugene R</creatorcontrib><creatorcontrib>MARINI, Angela</creatorcontrib><creatorcontrib>SAVARAJ, Niramol</creatorcontrib><creatorcontrib>ARDALAN, Bach</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FEUN, Lynn G</au><au>OBRIEN, Christopher</au><au>MOLINA, Enrique</au><au>RODRIGUEZ, Miguel</au><au>JEFFERS, Lenox</au><au>SCHIFF, Eugene R</au><au>MARINI, Angela</au><au>SAVARAJ, Niramol</au><au>ARDALAN, Bach</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2003</date><risdate>2003</risdate><volume>129</volume><issue>1</issue><spage>17</spage><epage>20</epage><pages>17-20</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><coden>JCROD7</coden><abstract>To study the combination of 5FUDR, recombinant leukocyte interferon (IFN), and doxorubicin in patients with unresectable hepatocellular carcinoma.
IFN was administered at a dose of 6 miu/m(2) subcutaneously followed in 2 h by doxorubicin 20 mg/m(2) intravenously. After doxorubicin, 5FUDR was given as a 24-h infusion at a starting dose of 80 mg/kg. The dose of IFN was escalated to three times a week if tolerated. Both doxorubicin and 5FUDR were administered once weekly.
There were 30 patients entered into the study. Among the 30 patients, there were two partial responses (7%) and one patient had stable disease. Toxicity was generally tolerable with fever, and chills, fatigue, and myelosuppression as the most common side effects.
This chemotherapy combination was generally well tolerated, but has limited activity in unresectable, advanced hepatocellular carcinoma.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>12618896</pmid><doi>10.1007/s00432-002-0398-2</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2003, Vol.129 (1), p.17-20 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_journals_220525363 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cancer Carcinoma, Hepatocellular - drug therapy Chemotherapy Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Doxorubicin - administration & dosage Drug Administration Schedule Female Floxuridine - administration & dosage Humans Infusions, Intravenous Interferons - administration & dosage Leukocytes Liver Liver Neoplasms - drug therapy Male Medical sciences Middle Aged Pharmacology. Drug treatments Recombinant Proteins - administration & dosage Treatment Failure |
| title | Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T05%3A05%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recombinant%20leukocyte%20interferon,%20doxorubicin,%20and%205FUDR%20in%20patients%20with%20hepatocellular%20carcinoma-A%20phase%20II%20trial&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=FEUN,%20Lynn%20G&rft.date=2003&rft.volume=129&rft.issue=1&rft.spage=17&rft.epage=20&rft.pages=17-20&rft.issn=0171-5216&rft.eissn=1432-1335&rft.coden=JCROD7&rft_id=info:doi/10.1007/s00432-002-0398-2&rft_dat=%3Cproquest_cross%3E701911801%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220525363&rft_id=info:pmid/12618896&rfr_iscdi=true |